Primary health centre

EMTECH Onboards SEC Ghana On Its Digital Regulatory Sandbox Platform

Retrieved on: 
Tuesday, September 20, 2022
Central bank, CBDC, Primary health centre, Central Bank of Liberia, IBM, CBN, Visa, Growth, Review, Google, Central Bank of Nigeria, Industry, Partnership, API, Bank, Public sector banks in India, CBL, Ecosystem, KPMG, Regulation, GLOBE, SEC, Financial technology, Federal Reserve Bank, Agricultural Development Bank of Ghana, DRP, Cryptocurrency

NEW YORK, NY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- EMTECH, an award-winning software company and first-of-its-kind provider of central banking infrastructure, has partnered with SEC Ghana to deploy its API-First Digital Regulatory Sandbox Platform to streamline regulatory sandboxing and supervision of capital market innovation.

Key Points: 
  • NEW YORK, NY, Sept. 20, 2022 (GLOBE NEWSWIRE) -- EMTECH, an award-winning software company and first-of-its-kind provider of central banking infrastructure, has partnered with SEC Ghana to deploy its API-First Digital Regulatory Sandbox Platform to streamline regulatory sandboxing and supervision of capital market innovation.
  • "EMTECH is delighted to deploy this modern innovation with SEC Ghana, says EMTECH Founder and CEO Carmelle Cadet.
  • Now partnered with SEC Ghana, their Digital Regulatory Sandbox platform will bridge the gaps between regulators and innovators in the financial services space with a developer-friendly design.
  • By digitizing access to central banking services, starting with the Digital Regulatory Sandbox and Regulatory Reporting APIs, EMTECHs open platform unlocks exceptional value for both fintechs and regulators.

Bank of Ghana Goes Live on EMTECH’s Regulatory Platform

Retrieved on: 
Tuesday, August 23, 2022
Software, Bank of Ghana, Primary health centre, BOG, Partnership, Technology, Regulation, FSP, Platform, Central bank, API, GLOBE, Compliance, Risk, Press release, Ecosystem, Bank, CBDC, Industry, Digital currency, Review, Central bank digital currency, Cryptocurrency, Medical device, Sandbox

NEW YORK, NY, Aug. 23, 2022 (GLOBE NEWSWIRE) -- EMTECH, a Modern Central Banking Infrastructure provider, announced today its API-First Digital Regulatory Sandbox Platform was selected by the Bank of Ghana to modernize its regulatory review process and regulatory reporting capabilities.

Key Points: 
  • NEW YORK, NY, Aug. 23, 2022 (GLOBE NEWSWIRE) -- EMTECH, a Modern Central Banking Infrastructure provider, announced today its API-First Digital Regulatory Sandbox Platform was selected by the Bank of Ghana to modernize its regulatory review process and regulatory reporting capabilities.
  • EMTECHs open platform digitizes access to central banking services starting with the Digital Regulatory Sandbox and Regulatory Reporting APIs.
  • The firms partnership with Bank of Ghana unlocks unprecedented value for both FSPs and regulators.
  • The Bank of Ghana has announced the Digital Regulatory Sandbox will welcome various Financial Service Providers, see the Sandbox Framework .

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
Monday, June 6, 2022
SD, Oncology, Immunotherapy, Veteran, FSP, GE, US, Society, Modified vaccinia Ankara, AACR, Neoplasm, LinkedIn, MVA, ASCO, Hope, Annual general meeting, Primary health centre, Pembrolizumab, City, American Association, MSI, American Society of Clinical Oncology, MSI-H, Patient, GENESIS, Gad, FDA, DNA, Tumor microenvironment, Trial of the century, Microsatellite instability, Association, Cancer, ELISpot, American Association for Cancer Research, Peptide, Safety, Vaccine, Pharmaceutical industry, Medical imaging

BASEL, Switzerland, June 6, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced first data from the completed Phase 1 trial evaluating NOUS-209 in combination with anti-PD-1 checkpoint inhibitor (pembrolizumab). The data, presented yesterday in a poster discussion session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated NOUS-209 to be safe, highly immunogenic and with promising signs of clinical efficacy.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: "These new data with all patients enrolled continues to reinforce our compelling and differentiating data for NOUS-209.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
Monday, June 6, 2022
SD, Oncology, Immunotherapy, Veteran, FSP, GE, US, Society, Modified vaccinia Ankara, AACR, Neoplasm, LinkedIn, MVA, ASCO, Hope, Annual general meeting, Primary health centre, Pembrolizumab, City, American Association, MSI, American Society of Clinical Oncology, MSI-H, Patient, GENESIS, Gad, FDA, DNA, Tumor microenvironment, Trial of the century, Microsatellite instability, Association, Cancer, ELISpot, American Association for Cancer Research, Peptide, Safety, Vaccine, Pharmaceutical industry, Medical imaging

BASEL, Switzerland, June 6, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vectored immunotherapies, today announced first data from the completed Phase 1 trial evaluating NOUS-209 in combination with anti-PD-1 checkpoint inhibitor (pembrolizumab). The data, presented yesterday in a poster discussion session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated NOUS-209 to be safe, highly immunogenic and with promising signs of clinical efficacy.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer vaccine targeting 209 shared neoantigens.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: "These new data with all patients enrolled continues to reinforce our compelling and differentiating data for NOUS-209.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
DNA, Immunotherapy, Cancer, Neoplasm, Annual general meeting, Modified vaccinia Ankara, AACR, Gad, MSI, SITC, US, FSP, Society, American Society of Clinical Oncology, Trial of the century, Veteran, FDA, Pembrolizumab, Peptide, Safety, ASCO, GE, LinkedIn, MVA, GENESIS, MSI-H, Primary health centre, Pharmaceutical industry, Vaccine

ASCO will be held virtually and in person in Chicago from 3 to 7th June.

Key Points: 
  • ASCO will be held virtually and in person in Chicago from 3 to 7th June.
  • Nouscom is a clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer vaccines.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom to Present Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022

Retrieved on: 
Friday, May 27, 2022
DNA, Immunotherapy, Cancer, Neoplasm, Annual general meeting, Modified vaccinia Ankara, AACR, Gad, MSI, SITC, US, FSP, Society, American Society of Clinical Oncology, Trial of the century, Veteran, FDA, Pembrolizumab, Peptide, Safety, ASCO, GE, LinkedIn, MVA, GENESIS, MSI-H, Primary health centre, Pharmaceutical industry, Vaccine

ASCO will be held virtually and in person in Chicago from 3 to 7th June.

Key Points: 
  • ASCO will be held virtually and in person in Chicago from 3 to 7th June.
  • Nouscom is a clinical stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer vaccines.
  • Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

Retrieved on: 
Monday, April 11, 2022
Microsatellite instability, LinkedIn, Individualized cancer immunotherapy, Veteran, Vaccination, DNA, Pembrolizumab, Lymphocyte, Immunotherapy, Trial of the century, ELISpot, Society, Cancer, GENESIS, Patient, FSP, Tumor microenvironment, AACR, Modified vaccinia Ankara, American Association, GE, Neoplasm, TCR, Association, Safety, Annual general meeting, Gad, Primary health centre, MSI-H, Oncology, Phenotype, SITC, PRS, MVA, Peptide, Society for Immunotherapy of Cancer, MSI, City, Pharmaceutical industry, Vaccine, Medical imaging

The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • The new translational data presented at AACR 2022 further supported these findings and demonstrated NOUS-209 is safe, highly immunogenic with promising signs of clinical efficacy.
  • In one of these three patients, vaccine-induced neoantigen specific TCR was tracked from periphery in the tumor biopsy post NOUS-209 treatment.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces New Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022

Retrieved on: 
Monday, April 11, 2022
Microsatellite instability, LinkedIn, Individualized cancer immunotherapy, Veteran, Vaccination, DNA, Pembrolizumab, Lymphocyte, Immunotherapy, Trial of the century, ELISpot, Society, Cancer, GENESIS, Patient, FSP, Tumor microenvironment, AACR, Modified vaccinia Ankara, American Association, GE, Neoplasm, TCR, Association, Safety, Annual general meeting, Gad, Primary health centre, MSI-H, Oncology, Phenotype, SITC, PRS, MVA, Peptide, Society for Immunotherapy of Cancer, MSI, City, Pharmaceutical industry, Vaccine, Medical imaging

The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The data were presented yesterday in a Late Breaking session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • The new translational data presented at AACR 2022 further supported these findings and demonstrated NOUS-209 is safe, highly immunogenic with promising signs of clinical efficacy.
  • In one of these three patients, vaccine-induced neoantigen specific TCR was tracked from periphery in the tumor biopsy post NOUS-209 treatment.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors

Retrieved on: 
Tuesday, April 5, 2022
Microsatellite instability, LinkedIn, Veteran, DNA, Pembrolizumab, Trial of the century, Immunotherapy, GENESIS, Cancer, FSP, AACR, Modified vaccinia Ankara, American Association, GE, Neoplasm, Association, Safety, Annual general meeting, Gad, Primary health centre, MSI-H, MVA, Peptide, MSI, Pharmaceutical industry, Medical imaging, Vaccine

NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer immunotherapy targeting shared neoantigens, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer immunotherapy targeting shared neoantigens, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.
  • Title: Characterization of immune correlates of clinical activity for NOUS-209, an Off-the-Shelf immunotherapy, with Pembrolizumab for treatment of tumors characterized by Microsatellite Instability (MSI).
  • The full abstract will be available on 8th April at 1pm ET here: https://www.abstractsonline.com/pp8/#!/10517/presentation/19995
    NOUS-209 is an off-the-shelf immunotherapy for Microsatellite Instable High (MSI-H) tumors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/

Nouscom Announces AACR 2022 Late-Breaking Presentation of Translational Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of MSI-H Solid Tumors

Retrieved on: 
Tuesday, April 5, 2022
Microsatellite instability, LinkedIn, Veteran, DNA, Pembrolizumab, Trial of the century, Immunotherapy, GENESIS, Cancer, FSP, AACR, Modified vaccinia Ankara, American Association, GE, Neoplasm, Association, Safety, Annual general meeting, Gad, Primary health centre, MSI-H, MVA, Peptide, MSI, Pharmaceutical industry, Medical imaging, Vaccine

NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer immunotherapy targeting shared neoantigens, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.

Key Points: 
  • NOUS-209, Nouscom's leadproduct, is an off-the-shelf cancer immunotherapy targeting shared neoantigens, administered in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab, for the treatment of Microsatellite Instable High (MSI-H) gastric, colorectal and gastro-esophageal junction solid tumors.
  • Title: Characterization of immune correlates of clinical activity for NOUS-209, an Off-the-Shelf immunotherapy, with Pembrolizumab for treatment of tumors characterized by Microsatellite Instability (MSI).
  • The full abstract will be available on 8th April at 1pm ET here: https://www.abstractsonline.com/pp8/#!/10517/presentation/19995
    NOUS-209 is an off-the-shelf immunotherapy for Microsatellite Instable High (MSI-H) tumors.
  • For more information on Nouscom, please visit the company's website at www.nouscom.com or follow us on LinkedIn at www.linkedin.com/company/nouscom-ag/